Factors enhanced seizure free with perampanel monotherapy in neurosurgical intensive care unit

Phase 2

Completed

• Conditions: Patients with first new onset focal seizure, with or without focal to bilateral tonic clonic seizures, and generalized tonic clonic seizures and had clinical information of the first seizure confirmed by EEG or 24 hours video EEG monitoring and received perampanel as the first antiseizure medication with monotherapy; Perampanel, monotherapy, Neurosurgical intensive care unit, focal-onset; seizures, focal to bilateral tonic-clonic seizures, and generalized tonic-clonic seizures, drug-resistant epilepsy, efficacy

• Registration Number: TCTR20240429003
• Lead Sponsor: Phramongkutklao Hospital Foundation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2024-04-15
• Study Start: 2024-04-29
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 76

Inclusion Criteria

Drug-resistant focal epilepsy patients over the age of 20 were invited to participate in the study at our Division. Drug-resistant epilepsies are defined as individuals who fail to achieve seizure free despite using two anti-seizure medicines, either polytherapy or sequential monotherapy, and adhering to a strict treatment regimen.

Exclusion Criteria

Patients who refused to fill out questionnaires for the trial were excluded.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
neurological outcome 6 month seizure frequency of 50% (50% responder rate) ,seizure outcom 6 months drug response and retention rate at 6 months

Secondary Outcome Measures

Name	Time	Method
treatment emergent adverse events 6 months modified ranking score at 6 months,factors associated with seizure-free 6 months protective factor in seizure free group